Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-549 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12305.165 | 0.9125 | 0.9334 | 2.7020 | |
| BT-549 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12305.165 | 0.8997 | 0.9232 | 2.7020 | |
| BT-549 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12305.165 | 0.8117 | 0.8514 | 2.7020 | |
| BT-549 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12305.165 | 0.8013 | 0.8426 | 2.7020 | |
| BT-549 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12305.165 | 0.3405 | 0.3423 | 2.7020 | |
| BT-549 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12305.165 | 0.0214 | -0.5176 | 2.7020 | |
| BT-549 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12305.165 | 0.0005 | -0.8811 | 2.7020 | |
| CAMA-1 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12070.158 | 1.0017 | 1.0030 | 1.1252 | |
| CAMA-1 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12070.158 | 1.0673 | 1.1191 | 1.1252 | |
| CAMA-1 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12070.158 | 1.0020 | 1.0035 | 1.1252 | |
| CAMA-1 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12070.158 | 1.1208 | 1.2134 | 1.1252 | |
| CAMA-1 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12070.158 | 0.8686 | 0.7646 | 1.1252 | |
| CAMA-1 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12070.158 | 0.9921 | 0.9859 | 1.1252 | |
| CAMA-1 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12070.158 | 0.6642 | 0.3903 | 1.1252 | |
| CAMA-1 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12070.158 | 0.0162 | -0.9487 | 1.1252 | |
| CAMA-1 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12070.158 | 0.0122 | -0.9601 | 1.1252 | |
| HCC1143 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12112.158 | 0.8558 | 0.8380 | 1.8430 | |
| HCC1143 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12112.158 | 0.8464 | 0.8269 | 1.8430 | |
| HCC1143 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12112.158 | 0.9135 | 0.9041 | 1.8430 | |
| HCC1143 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12112.158 | 0.9315 | 0.9244 | 1.8430 | |
| HCC1143 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12112.158 | 0.7568 | 0.7194 | 1.8430 | |
| HCC1143 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12112.158 | 0.7692 | 0.7346 | 1.8430 | |
| HCC1143 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12112.158 | 0.5310 | 0.4186 | 1.8430 | |
| HCC1143 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12112.158 | 0.0716 | -0.5216 | 1.8430 | |
| HCC1143 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12112.158 | 0.0066 | -0.8683 | 1.8430 |